Impact of Mézières Rehabilitative Method in Patients with Parkinson’s Disease: A Randomized Controlled Trial

Table 4

Scales and clinical evaluation: comparison for Mézières group at 3 evaluation times.

Scales and clinical evaluations for Mézières group	T0		T1		T2				Effect
	Median	IQR	Median	IQR	Median	IQR
VAS (cm)	3.0	4.0	2.0	4.0	1.5	4.0	<0.001
SF-36 PF	72.5	33.8	75.0	15.0	85.0	25.0	0.014	—
SF-36 RP	75.0	72.5	100.0	50.0	100.0	37.5	0.002	1	0.24
SF-36 BP	62.0	22.3	62.0	30.0	72.0	43.5	0.598	—
SF-36 GH	42.0	29.0	47.0	25.0	42.0	37.5	0.198	—
SF-36 VT	50.0	15.0	57.5	15.0	55.0	27.5	0.018	—
SF-36 SF	75.0	34.8	87.3	25.0	87.5	25.0	0.002	—
SF-36 RE	100.0	66.7	100.0	33.8	100.0	33.0	0.368	—
BBS	48.0	6.5	54.5	8.0	51.5	7.5	<0.001
Trunk flexion test (cm)	10.5	10.0	10.0	11.8	8.0	12.0	<0.001
FGA	15.0	5.0	9.0	6.0	8.0	6.0	<0.001
MPAS	37.0	16.0	47.0	13.5	47.0	14.0	<0.001
SMWT (min)	467.5	157.5	510.0	171.3	480.0	277.5	0.081	—
UPDRS Part I	10.0	9.0	7.5	7.0	5.0	7.0	<0.001
UPDRS Part II	9.0	6.8	6.0	5.8	6.0	5.5	<0.001
UPDRS Part III	15.5	10.8	10.0	8.5	10.0	9.0	<0.001
UPDRS Total	38.0	20	27.0	12.5	23.0	16.5	<0.001

Group A: Mézières treatment group; IQR: interquartile range; VAS: Visual Analog Scale; SF-36: Short Form 36 Health Survey; PF: physical functioning; PR: physical role functioning; BD: bodily pain; GH: general health perceptions; VT: vitality; SF: social role functioning; RE: emotional role functioning; MH: mental health; BBS: Berg Balance Scale; FGA: Functional Gait Assessment; MPAS: Modified Parkinson’s Activity Scale; SMWT: six-minute walking test; UPDRS: Unified Parkinson’s Disease Rating Scale. value obtained by Friedman test. Significant comparisons obtained by Wilcoxon test with Bonferroni correction (0.017 is the critical level of significance of Bonferroni correction, i.e., 0.05/3: versus ; versus ; versus ; not significant comparisons). Effect size for the post hoc comparison. Bold font indicates statistical significance.